TGA Sues BioV8 Directors Over Illegal Peptide Ads

Australia’s Therapeutic Goods Administration has filed Federal Court proceedings against a liquidated peptide seller and, notably, against its two former directors personally — alleging the company’s advertising promoted prescription-only peptides as treatments for cancer, HIV/AIDS and mental illness, in breach of the Therapeutic Goods Act 1989.

What TGA alleges

TGA's claim centres on advertising, not manufacturing or supply directly: between 6 June 2024 and 14 July 2025, the company then known as BioV8 Pty Ltd allegedly advertised BPC-157, CJC-1295 and GHRP-6 — peptides with no TGA-approved therapeutic indication for consumer use — on its website and social media channels, with claims that they could treat serious diseases including cancer, HIV/AIDS and mental illness. Under the Therapeutic Goods Act 1989, references to a list of serious conditions are treated as “restricted” or outright “prohibited” representations: advertising a therapeutic good as capable of treating them requires prior TGA approval that BioV8 is alleged not to have held. TGA is asking the Federal Court for declarations that the conduct breached the Act, plus pecuniary penalties.

Pursuing directors personally, even after liquidation

The detail regulatory and compliance teams at wellness, telehealth and peptide-adjacent businesses should note is who TGA named: not just the corporate entity, now in liquidation and renamed A.C.N. 641 483 703 Pty Ltd, but its two former directors, Edward McGill and Nicholas Austin, in their personal capacity. A company folding does not by itself end its former officers' exposure for conduct they are alleged to have directed or permitted while running it — and TGA is seeking penalties against McGill and Austin directly, independent of what happens to the company. TGA's own release states that proceeding against the corporate entity itself requires the Federal Court's leave because it is in liquidation, a procedural wrinkle that does not apply to the claims against the individuals.

Part of a widening enforcement push

BioV8 is not TGA's first swing at the peptide-advertising space. The regulator previously won a $10 million penalty against Peptide Clinics Pty Ltd over comparable advertising breaches — a separate, earlier case that Regulatory News is not conflating with this one, but that signals the scale of penalty TGA is prepared to pursue in this category. Peptides marketed for muscle recovery, longevity, weight loss and similar “biohacking” uses sit in a regulatory grey zone that has drawn escalating attention from TGA and, separately, from FDA warning-letter sweeps in the United States. For any company advertising peptide products into the Australian market — including via social media reaching Australian consumers from overseas — BioV8 is a reminder that TGA is treating restricted and prohibited representations as a priority enforcement target, and that it will name individual officers rather than let a corporate wind-down close the file.

What is not yet resolved

As of this writing, no hearing date or penalty amount has been reported for the BioV8 matter, and Regulatory News found no primary TGA deep-link publishing the case beyond its media-releases index — the facts here are corroborated across three independent outlets citing TGA's release, not a direct TGA document Regulatory News could read itself. Anyone tracking the matter for compliance purposes should watch the Federal Court of Australia's public listings and TGA's media-releases page directly as the case proceeds.

Frequently asked questions

Who is TGA pursuing, and where?

The Therapeutic Goods Administration has filed proceedings in the Federal Court of Australia against A.C.N. 641 483 703 Pty Ltd (in liquidation, formerly BioV8 Pty Ltd) and its two former directors, Edward “Teddy” McGill and Nicholas Austin, personally.

What is BioV8 accused of advertising?

Between 6 June 2024 and 14 July 2025, the company allegedly advertised the peptides BPC-157, CJC-1295 and GHRP-6 on its website and social media with claims they could treat cancer, HIV/AIDS and mental illness — representations the Therapeutic Goods Act 1989 restricts or prohibits from being advertised without TGA approval.

Why pursue individuals if the company is in liquidation?

Liquidation does not extinguish a company's officers' personal exposure for conduct they allegedly directed or permitted. TGA is seeking declarations and pecuniary penalties against McGill and Austin directly; proceeding against the corporate entity itself additionally requires the Federal Court's leave because it is in liquidation.

Is this part of a wider pattern?

Yes. TGA previously secured a $10 million penalty against Peptide Clinics Pty Ltd for similar advertising breaches — a separate, earlier case, not the same matter as BioV8. Regulatory News is treating the two as a related enforcement trend, not identical proceedings.